Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth



P/B 5.71
FBT's P/B is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. FBT: 5.71 )
Ranked among companies with meaningful P/B only.
FBT' s P/B Range Over the Past 10 Years
Min: 0  Med: 0 Max: 6.17
Current: 5.71

Buy Back


More Statistics

Short Percentage of Float0.00%
52-Week Range $78.18 - 114.62
Shares Outstanding (Mil)8,700,002.00
» More Articles for FBT


Articles On GuruFocus.com
Semiconductor Industry Offers High Growth Potential Sep 28 2016 
Australian Scentre Pays 4.4% Dividend Sep 28 2016 
Primo Water Reports 210% Increase in Net Income Sep 28 2016 
American Financial CEO Sells Shares in Company Sep 28 2016 
Legendary Value Investor Jean-Marie Eveillard Will Speak at 2017 GuruFocus Value Conference, Omaha Sep 28 2016 
Ariel Funds Comments on Harman Intl Industries Inc. Sep 28 2016 
Ariel Funds Comments on Baidu Inc. Sep 28 2016 
Ariel Funds Comments on GlaxoSmithKline plc Sep 28 2016 
Ariel Funds Comments on Johnson & Johnson Sep 28 2016 
Qualcomm Holding On in the Face of Adversity Sep 28 2016 

More From Other Websites
BioMarin to Cross $1 Billion Revenue in 2016 Sep 27 2016
Higher Discontinuations Are among Orkambi’s Concerns Sep 26 2016
How Ionis Pharmaceuticals’ Valuation Compares to Its Peers Sep 20 2016
Sarepta Stock Surge Boosts Some Biotech ETFs But Not Others Sep 19 2016
Inside the Recent Surge in Biotech ETFs Sep 14 2016
Technicals, Politics Clash for Biotech ETFs Sep 06 2016
How Is Incyte’s Only FDA-Approved Drug Performing? Sep 05 2016
Clinton's Proposal To Combat Drug Price Hikes Sep 02 2016
Biotech ETF Industry Outlook Aug 31 2016
Biotech Leads the Way in Health Care Stocks to Boost 401(k) Returns Aug 31 2016
United Therapeutics Makes Novel Technologies a Priority Aug 31 2016
Biotech ETFs Back In The Spotlight Aug 30 2016
What Should We Expect from BioMarin’s Kuvan in 2016? Aug 26 2016
What’s BioMarin’s Expected Revenue Growth in 2016 and 2017? Aug 25 2016
Did Hillary Clinton's Tweet Cause the Sell-Off in Mylan (MYL) Stock? Aug 24 2016
How Xtandi Fueled Big Pharmaceutical Interest in Medivation Aug 24 2016
Another Endorsement for Biotech ETFs Aug 16 2016
Biotech Breakout: Take 3 Aug 04 2016
Big Biotech Buyout Banter Buoys IBB Aug 02 2016
How Much Will BioMarin’s Kuvan Fetch in 2Q16? Aug 02 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)